Acadia Pharma (ACAD) Tops Q1 EPS by 13c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $20.68 -6.76%
Revenue Growth %: +19.3%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: +19.3%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.11, $0.13 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $244.32 million versus the consensus estimate of $239.55 million.
GUIDANCE:
Acadia Pharma sees FY2025 revenue of $1.03-1.09 billion, versus the consensus of $1.06 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
- Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Citizens on Ph2 Miss for Remlifanserin
- NV Gold closes final tranche of private placement, raising $1.4M
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
